NRX Pharmaceuticals (NRXP) Accounts Payables (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Accounts Payables of $4.4 million for Q1 2026, up 2.04% year-over-year from $4.3 million in Q1 2025, and up 3.02% quarter-over-quarter from $4.3 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Accounts Payables (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Accounts Payables for 10 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 2.04% year-over-year to $4.4 million; the TTM figure through Mar 2026 stood at $4.4 million (up 2.04% YoY), while the FY2025 annual figure was $4.3 million, up 3.39% from the prior year.
- Accounts Payables grew to $4.4 million in Q1 2026 per NRXP's latest filing, from $4.3 million in the prior quarter.
- Across five years, Accounts Payables topped out at $6.3 million in Q1 2024 and bottomed at $2.1 million in Q4 2022.
- Historically, Accounts Payables has averaged $3.9 million across 5 years, with a median of $4.3 million in 2025.
- On a YoY basis, Accounts Payables climbed as much as 569.73% in 2022 and fell as far as 61.0% in 2022.
- NRX Pharmaceuticals' Accounts Payables stood at $2.1 million in 2022, then jumped by 123.12% to $4.6 million in 2023, then dropped by 10.84% to $4.1 million in 2024, then rose by 3.39% to $4.3 million in 2025, then increased by 3.02% to $4.4 million in 2026.
- Business Quant data shows NRXP's Accounts Payables at $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 3.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.40 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.26 Mn |
| Jun 30, 2025 | 3.63 Mn |
| Mar 31, 2025 | 4.31 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.87 Mn |
| Jun 30, 2024 | 5.02 Mn |
| Mar 31, 2024 | 6.27 Mn |
| Dec 31, 2023 | 4.63 Mn |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 3.78 Mn |
| Dec 31, 2022 | 2.08 Mn |
| Sep 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 3.08 Mn |
| Mar 31, 2022 | 4.31 Mn |
| Dec 31, 2021 | 3.69 Mn |
| Sep 30, 2021 | 5.56 Mn |
| Jun 30, 2021 | 6.27 Mn |